VKTX Viking Therapeutics, Inc.
VKTX Viking Therapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $34.93 · VWAP $33.69 · -27.6% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, CFO + 1 other sold $6.3M, Jul 29
Coverage
2 watchlists
VKTX Price Structure
Loading timeframes…
Peers
Every watchlist VKTX belongs to, members best 30-day change first — VKTX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@peptide-economy
@biotech-capital-cycle
Reported the quarter ending 2026-06-30: revenue $0, diluted EPS -$1.10, net income -$128M (SEC filing, revenue corroborated by the desk's provider cache). Across the print the stock moved -2.2% (close before → first close after).
full note →Against street estimates
How VKTX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about VKTX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 23
- sec.gov
- Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 - Oct 21, 2026
- Viking Therapeutics - Overview
- Viking Therapeutics (VKTX) Stock Price & Overview
- Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes - Sep 28, 2026
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
VKTX research tape
56 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to VKTX.
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet